Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Common Equity (2023 - 2025)

Metagenomi (MGX) has disclosed Common Equity for 3 consecutive years, with $158.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 32.47% to $158.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.6 million through Dec 2025, down 32.47% year-over-year, with the annual reading at $158.6 million for FY2025, 32.47% down from the prior year.
  • Common Equity for Q4 2025 was $158.6 million at Metagenomi, down from $178.4 million in the prior quarter.
  • The five-year high for Common Equity was $275.6 million in Q1 2024, with the low at -$135.6 million in Q4 2023.
  • Average Common Equity over 3 years is $121.1 million, with a median of $187.1 million recorded in 2025.
  • The sharpest move saw Common Equity soared 214997.37% in 2024, then crashed 32.47% in 2025.
  • Over 3 years, Common Equity stood at -$135.6 million in 2023, then soared by 273.22% to $234.9 million in 2024, then plummeted by 32.47% to $158.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $158.6 million, $178.4 million, and $195.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.